Zdrowie i gospodarka · 14/03/2018

FDA Releases Updated Guidance on Deoxyribonucleic Acid Reactive Impurities in Pharmaceuticals

The Food and Drug Administration (FDA) has announced the availability of an updated guidance document, M7(R1), which provides new guidance on assessing and controlling mutagenic impurities in pharmaceuticals to limit potential carcinogenic risk.